Related Experiment Video
Updated: Aug 4, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes
1Division of Cardiovascular Diseases, Department of Internal Medicine, University Hospital, University of Michigan, Ann Arbor, MI 48109, USA.
Insights
Platelet glycoprotein (GP) IIb/IIIa inhibitors reduce ischemic events in high-risk acute coronary syndrome patients. Despite proven benefits, underutilization persists, highlighting a need for improved treatment strategies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet glycoprotein (GP) IIb/IIIa inhibitors are crucial in managing acute coronary syndromes.
- These agents prevent fibrinogen binding and platelet aggregation, reducing ischemic complications.
Purpose of the Study:
- To evaluate the efficacy of parenteral GP IIb/IIIa inhibitors in high-risk acute coronary syndrome patients.
- To assess the current utilization patterns and identify barriers to therapy.
Main Methods:
- Meta-analysis of 6 randomized controlled trials involving parenteral GP IIb/IIIa inhibitors.
- Analysis of patient subgroups including those undergoing percutaneous coronary intervention, high TIMI risk score, elevated troponin, and diabetes mellitus.
Main Results:
- Significant reduction in death and myocardial infarction observed in high-risk patient populations.
- Identified underutilization of these agents despite guideline recommendations for specific indications.
Conclusions:
- Parenteral GP IIb/IIIa inhibitors offer significant benefits for high-risk acute coronary syndrome patients.
- Addressing underutilization is critical to improve patient outcomes; further research into optimal dosing is warranted.
Abstract:
Platelet glycoprotein (GP) IIb/IIIa inhibitors prevent fibrinogen binding and platelet aggregation. They decrease ischemic complications associated with non-ST segment elevation acute coronary syndromes and percutaneous coronary intervention. Meta-analyses of 6 randomized trials of parenteral GP IIb/IIIa inhibitors in patients with acute coronary syndromes suggest a significant reduction in death and myocardial infarction in high risk patients. These include patients undergoing early percutaneous coronary intervention or those with high TIMI risk score, elevated troponin values, or diabetes mellitus. Despite guideline recommendations supporting therapy for these indications, only a minority of appropriate candidates are being treated. The risk of major bleeding is small; thrombocytopenia can result from abciximab therapy. Optimal dosing strategies continue to evolve.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

